Concentrated insulins: the new basal insulins

References

• BaysHEChapmanRHGrandySSHIELD Investigators’ GroupThe relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveysInt J Clin Pract200761573774717493087
   PubMed Web of Science ®Google Scholar
• RiddleMCRosenstockJGerichJInsulin Glargine 4002 Study InvestigatorsThe treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patientsDiabetes Care200326113080308614578243
   PubMed Web of Science ®Google Scholar
• PorcellatiFRossettiPBusciantellaNRComparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover studyDiabetes Care200730102447245217623819
   PubMed Web of Science ®Google Scholar
• AbaliSTuranSAtayZGuranTHalilogluBBereketAHigher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitusPediatr Diabetes201516536136625039448
   PubMed Web of Science ®Google Scholar
• AshwellSGGebbieJHomePDTwice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspartDiabet Med200623887988616911626
   PubMed Web of Science ®Google Scholar
• BryantGAMcDanelDLHornerKEFarrisKBNewkirkENEvaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemirPharmacotherapy2013331566223307546
   PubMed Web of Science ®Google Scholar
• SegalAREl SayedNAre you ready for more insulin concentrations?J Diabetes Sci Technol20159233133825385945
   PubMedGoogle Scholar
• LaneWSCochranEKJacksonJAHigh-dose insulin therapy: is it time for U-500 insulin?Endocr Pract2009151717919211405
   PubMed Web of Science ®Google Scholar
• KhanMLeeYThe pharmacokinetics and pharmacodynamics of regular U500 insulin in healthy non-obese subjectsDiabetes200756suppl 1A334A335
   Google Scholar
• DavidsonMBNavarMDEcheverryDDuranPU-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patientsDiabetes Care201033228128319910500
   PubMed Web of Science ®Google Scholar
• de la PenaARiddleMMorrowLAPharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjectsDiabetes Care201134122496250121994429
   PubMed Web of Science ®Google Scholar
• JonassenIHavelundSHoeg-JensenTSteensgaardDBWahlundPORibelUDesign of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulinPharm Res20122982104211422485010
   PubMed Web of Science ®Google Scholar
• KorsatkoSDellerSKoehlerGA comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludecClin Drug Investig2013337515521
   PubMed Web of Science ®Google Scholar
• HeiseTHovelmannUNosekLBottcherSGranhallCHaahrHInsulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile compared with insulin glargineEndocr Abstr201228188
   Google Scholar
• HeiseTHermanskiLNosekLFeldmanARasmussenSHaahrHInsulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetesDiabetes Obes Metab201214985986422594461
   PubMed Web of Science ®Google Scholar
• HeiseTNosekLBottcherSGHastrupHHaahrHUltra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetesDiabetes Obes Metab2012141094495022726241
   PubMed Web of Science ®Google Scholar
• HeiseTKorsatkoSNosekLSteady state is reached within 2–3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of actionJ Diabetes Epub2015112
   PubMed Web of Science ®Google Scholar
• NosekLCoesterHVRoepstorffCGlucose-lowering effect of insulin degludec is independent of subcutaneous injection regionClin Drug Investig2014349673679
   PubMed Web of Science ®Google Scholar
• KissIAroldGRoepstorffCBottcherSGKlimSHaahrHInsulin degludec: pharmacokinetics in patients with renal impairmentClin Pharmacokinet201453217518324163264
   PubMed Web of Science ®Google Scholar
• KupcovaVAroldGRoepstorffCHojbjerreMKlimSHaahrHInsulin degludec: pharmacokinetic properties in subjects with hepatic impairmentClin Drug Investig2014342127133
   PubMed Web of Science ®Google Scholar
• SteinstraesserASchmidtRBergmannKDahmenRBeckerRHInvestigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/mlDiabetes Obes Metab201416987387624571126
   PubMed Web of Science ®Google Scholar
• BeckerRHDahmenRBergmannKLehmannAJaxTHeiseTNew insulin glargine 300 Units. mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units. mL-1Diabetes Care201538463764325150159
   PubMed Web of Science ®Google Scholar
• BeckerRHNowotnyITeichertLBergmannKKapitzaCLow within- and between-day variability in exposure to new insulin glargine 300 U/mlDiabetes Obes Metab201517326126725425394
   PubMed Web of Science ®Google Scholar
• TillnerJBergmannKTeichertLDahmenRHeiseTBeckerREuglycemic single dose clamp profile of new insulin glargine formulation in subjects with type 1 diabetes is flat and prolongedBarcelona2013
   Google Scholar
• Sanofi-Aventis [webpage on the Internet]Toujeo [Package Insert] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206538lbl.pdfAccessed November 05, 2015
   Google Scholar
• PschererSSchreyer-ZellGGottsmannMExperience with insulin glargine in patients with end-stage renal diseaseDiabetes200251suppl 2A53
   Google Scholar
• ToyodaMKimuraMYamamotoNMiyauchiMUmezonoTSuzukiDInsulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysisJ Nephrol201225698999522307438
   PubMed Web of Science ®Google Scholar
• DaileyAMWilliamsSTanejaDTannockLRClinical efficacy and patient satisfaction with U-500 insulin useDiabetes Res Clin Pract201088325926420226557
   PubMed Web of Science ®Google Scholar
• NayyarVJarvisJLawrenceILong-term follow up of patients on U-500 insulin: a case seriesPract Diabetes Int2010275194197
   Google Scholar
• BoldoAComiRJClinical experience with U500 insulin: risks and benefitsEndocr Pract2012181566121803710
   PubMed Web of Science ®Google Scholar
• LaneWSWeinribSLRappaportJMHaleCBFarmerLKLaneRSThe effect of long-term use of U-500 insulin via continuous subcutaneous infusion on durability of glycemic control and weight in obese, insulin-resistant patients with type 2 diabetesEndocr Pract201319219620123186973
   PubMed Web of Science ®Google Scholar
• LaneWSWeinribSLRappaportJMPrzestrzelskiTA prospective trial of U500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and severe insulin resistanceEndocr Pract201016577878420350913
   PubMed Web of Science ®Google Scholar
• ReutrakulSWroblewskiKBrownRLClinical use of U-500 regular insulin: review and meta-analysisJ Diabetes Sci Technol20126241242022538155
   PubMedGoogle Scholar
• DaileyAMGibertJATannockLRDurability of glycemic control using U-500 insulinDiabetes Res Clin Pract201295334034422088791
   PubMed Web of Science ®Google Scholar
• HellerSBuseJFisherMInsulin degludec, an ultralongacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN basal-bolus type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trialLancet201237998251489149722521071
   PubMed Web of Science ®Google Scholar
• BirkelandKIHomePDWendischUInsulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargineDiabetes Care201134366166521270174
   PubMed Web of Science ®Google Scholar
• MathieuCHollanderPMiranda-PalmaBEfficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extensionJ Clin Endocrinol Metab20139831154116223393185
   PubMed Web of Science ®Google Scholar
• BodeBWChaykinLBSussmanAMEfficacy and safety of insulin degludec 200 U/mL and insulin degludec 100 U/mL in patients with type 2 diabetes (begin: compare)Endocr Pract201420878579124518180
   PubMed Web of Science ®Google Scholar
• GoughSCBhargavaAJainRMersebachHRasmussenSBergenstalRMLow-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trialDiabetes Care20133692536254223715753
   PubMed Web of Science ®Google Scholar
• RatnerREGoughSCMathieuCHypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trialsDiabetes Obes Metab201315217518423130654
   PubMed Web of Science ®Google Scholar
• SorliCWarrenMOyerDMersebachHJohansenTGoughSCElderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trialsDrugs Aging201330121009101824170235
   PubMed Web of Science ®Google Scholar
• HomePBergenstalRRiddleMGlycemic control and hypoglycemia with new insulin glargine 300 U/mL in people with T1DM (EDITION 4)Diabetes201463suppl 1ALB19
   Google Scholar
• RiddleMCYki-JarvinenHBolliGBOne-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extensionDiabetes Obes Metab201517983584225846721
   PubMed Web of Science ®Google Scholar
• BolliGBRiddleMCBergenstalRMNew insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)Diabetes Obes Metab201517438639425641260
   PubMed Web of Science ®Google Scholar
• RitzelRRousselRBolliGBPatient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetesDiabetes Obes Metab201517985986725929311
   PubMed Web of Science ®Google Scholar
• Yki-JarvinenHBergenstalRZiemenMNew insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2)Diabetes Care201437123235324325193531
   PubMed Web of Science ®Google Scholar
• MatsuhisaMKkoyamaMChengXShimizuSHiroseTNew insulin glargine 300 U/mL: glycemic control and hypoglycemia in Japanese people with T1DM (EDITION JP1)Diabetes201463suppl 1ALB22
   Google Scholar
• RiddleMBolliGHomePNew insulin glargine 300 U/mL: efficacy and safety of adaptable vs fixed dosing intervals in people with T2DMCan J Diabetes2014385S53
   PubMedGoogle Scholar
• RiddleMCBolliGBZiemenMNew insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1)Diabetes Care201437102755276225078900
   PubMed Web of Science ®Google Scholar
• TerauchiYMasayoshiKChengXShimizuSHiroseTGlycemic control and hypoglycemia in Japanese people with T2DM receiving new insulin glargine 300 U/mL in combination with OADs (EDITION JP2)Diabetes201463suppl 1ALB24
   Google Scholar
• ClinicalTrials.gov [webpage on the Internet]Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation with Lantus Available from: https://clinicaltrials.gov/ct2/show/NCT01195454?term=NCT01195454&rank=1Accessed November 04, 2015
   Google Scholar
• ZiesmerAEKellyKCGuerraPAGeorgeKGDunnFLU500 regular insulin use in insulin-resistant type 2 diabetic veteran patientsEndocr Pract2012181343821742613
   PubMed Web of Science ®Google Scholar
• Novo-Nordisk [webpage on the Internet]Insulin degludec and insulin degludec/insulin aspart treatment to improve glycemic control in patients with diabetes mellitus [Package Insert] Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM327017.pdfAccessed November 05, 2015
   Google Scholar
• ClinicalTrials.gov [webpage on the Internet]A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) Available from: https://clinicaltrials.gov/ct2/show/NCT01959529?term=NCT01959529&rank=1Accessed November 05, 2015
   Google Scholar
• KapitzaCBodeBIngwersenSHJacobsenLVPoulsenPPreserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapyJ Clin Pharmacol Epub2015521
   Web of Science ®Google Scholar
• RiddleMCForstTAronsonRAdding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)Diabetes Care20133692497250323564915
   PubMed Web of Science ®Google Scholar
• EbyELZagarAJWangPHealthcare costs and adherence associated with human regular u-500 versus high-dose U-100 insulin in patients with diabetesEndocr Pract201420766367024449672
   PubMed Web of Science ®Google Scholar
• EricssonAPollockRFHuntBValentineWJEvaluation of the cost-utility of insulin degludec vs insulin glargine in SwedenJ Med Econ201316121442145224147661
   PubMedGoogle Scholar
• EvansMWoldenMGundgaardJChubbBChristensenTCost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin – from the UK health care cost perspectiveDiabetes Obes Metab201416436637524373113
   PubMed Web of Science ®Google Scholar
• AnderbroTAmsbergSAdamsonUFear of hypoglycaemia in adults with type 1 diabetesDiabet Med201027101151115820854383
   PubMed Web of Science ®Google Scholar
• VenemanTMitrakouAMokanMCryerPGerichJInduction of hypoglycemia unawareness by asymptomatic nocturnal hypoglycemiaDiabetes1993429123312378349033
   PubMed Web of Science ®Google Scholar
• FrierBMHow hypoglycaemia can affect the life of a person with diabetesDiabetes Metab Res Rev2008242879218088077
   PubMed Web of Science ®Google Scholar
• DolbergBKLenhardMJSuccessful outcome of pregnancy in a patient with generalized lipoatrophic diabetes mellitusEndocr Pract200061343611419925
   PubMedGoogle Scholar
• Drugs.com [webpage on the Internet]Humulin R (concentrated) Price, Coupons, and Patient Assistance Programs Available from: http://www.drugs.com/price-guide/humulin-r-concentratedAccessed December 23, 2015
   Google Scholar
• Tresiba [webpage on the Internet] Available from: http://www.goodrx.com/tresiba?drug-name=tresibaAccessed December 23, 2015
   Google Scholar
• Drugs.com [webpage on the Internet]Toujeo Solostar Prices, Coupons and Patient Assistance Programs Available from: http://www.drugs.com/price-guide/toujeo-solostarAccessed December 23, 2015
   Google Scholar
• Sanofi-Aventis [webpage on the Internet]Toujeo [Package Insert]; EMA Summary of Product Characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000309/WC500047935.pdfAccessed December 25, 2015
   Google Scholar
• KurtzhalsPHeiseTStraussHMMulti-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludecPaper presented at: American Diabetes Association (ADA) 71st Scientific SessionJune, 2011San Diego, CA
   Google Scholar